Associate Member, Laboratory of Cancer Immunotherapy and Director, Immune Monitoring Laboratory at the EACRI
Dr. Redmond received his undergraduate degree in Biology at the University of California, Davis prior to pursuing a PhD in Immunology at The Scripps Research Institute in La Jolla, CA. His doctoral studies focused on understanding how defects in the regulation of cytotoxic (killer) CD8 T lymphocytes leads to the onset of autoimmune (type 1) diabetes. After obtaining his PhD, Dr. Redmond joined Dr. Andrew Weinberg’s laboratory at the Earle A. Chiles Research Institute (EACRI) at Providence Cancer Institute in Portland, OR. Dr. Redmond’s post-doctoral research focused on tumor immunotherapy, which harnesses the power of the patient’s own immune system to seek out and destroy tumors. Specifically, he investigated the mechanisms by which an agonist anti-OX40 mAb enhanced CD8 T cell function to eradicate tumors. Currently, Dr. Redmond is an Associate Member, Laboratory of Cancer Immunotherapy and Director, Immune Monitoring Laboratory at the EACRI and an Adjunct Assistant Professor in the Department of Molecular Microbiology and Immunology at Oregon Health & Science University. His work seeks to elucidate the mechanisms by which combinatorial approaches to cancer immunotherapy augments the development of effector CD8 T cells capable of eliminating tumors.
×
About William L. Redmond, PhD
Dr. Redmond received his undergraduate degree in Biology at the University of California, Davis prior to pursuing a PhD in Immunology at The Scripps Research Institute in La Jolla, CA. His doctoral studies focused on understanding how defects in the regulation of cytotoxic (killer) CD8 T lymphocytes leads to the onset of autoimmune (type 1) diabetes. After obtaining his PhD, Dr. Redmond joined Dr. Andrew Weinberg’s laboratory at the Earle A. Chiles Research Institute (EACRI) at Providence Cancer Institute in Portland, OR. Dr. Redmond’s post-doctoral research focused on tumor immunotherapy, which harnesses the power of the patient’s own immune system to seek out and destroy tumors. Specifically, he investigated the mechanisms by which an agonist anti-OX40 mAb enhanced CD8 T cell function to eradicate tumors. Currently, Dr. Redmond is an Associate Member, Laboratory of Cancer Immunotherapy and Director, Immune Monitoring Laboratory at the EACRI and an Adjunct Assistant Professor in the Department of Molecular Microbiology and Immunology at Oregon Health & Science University. His work seeks to elucidate the mechanisms by which combinatorial approaches to cancer immunotherapy augments the development of effector CD8 T cells capable of eliminating tumors.
| Present | Associate Member, Laboratory of Cancer Immunotherapy and Director, Immune Monitoring Laboratory at the EACRI, Providence ‐ Earle A. Chiles Research Institute, Providence Cancer Institute | |
|
|
||
Disciplines
Grants
| 2015 - 2018 | Career Catalyst Research Grant |
| Susan G. Komen | |
| 2010 - 2014 | Pathway to Independence Award (K99) |
| NIH/NCI | |
| 2011 - 2013 | V Scholar |
| V Foundation | |
| 2011 - 2011 | Junior Faculty Travel Grant, Annual Meeting, San Francisco, CA |
| American Association of Immunologists | |
| 2006 - 2009 | Sam E. and Kathleen L. Henry Post-doctoral Fellowship |
| American Cancer Society | |
| 2001 - 2004 | Scholar, Pre-doctoral Fellowship |
| Achievement Rewards for College Scientists (ARCS) Foundation |
Professional Service and Affiliations
| 2017 - Present | Chair, Institutional Biosafety Committee | 2017 - Present | Member, Translational Oncology Research Program, Knight Cancer Institute, OHSU | 2016 - Present | Member, European Academy of Tumor Immunology | 2015 - Present | Associate Editor, Journal for Immunotherapy of Cancer | 2013 - Present | Member, SITC Council for Immunotherapy Education & Outreach (CIEO) | 2011 - Present | Member, American Association for Cancer Research | 2009 - Present | Member, American Association of Immunologists | 2009 - Present | Member, Society for Immunotherapy of Cancer (SITC) | 2016 | Co-Chair, Improving Anti-tumor Efficacy of T Cells, American Association of Immunologists Annual Meeting | 2016 | Co-Chair, Overcoming suppression in the prostate cancer tumor microenvironment, Prostate Cancer Foundation | 2013 - 2016 | Member, EACRI IACUC | 2012 - 2016 | Member, Federation of Clinical Immunology Societies | 2014 - 2015 | Co-Chair, Prostate Cancer Foundation Young Investigator’s Working Group; Tumor Microenvironment and Immunology | 2009 - 2015 | Member, SITC Early Career Scientists Committee | 2011 - 2013 | Co-Chair, SITC Early Career Scientists Committee | 2012 | Co-organizer, 3rd Annual OHSU/EACRI Portland Immunology Retreat |
Honors and Awards
- • American Association of Immunologists - Cynthia Chambers Memorial – eBioscience Junior Faculty Award, Annual Meeting, San Francisco, CA (2011)
- • NIH/NCI – Pathway to Independence Award (K99) (2010-2014)
- • Prostate Cancer Foundation – Young Investigator Award (2008-2011)
- • American Association of Immunologists - Trainee Abstract Award, Annual Meeting, Seattle, WA (2009)
- • American Association of Immunologists - Trainee Abstract Award, Annual Meeting, San Diego, CA (2008)
Courses
- Oregon Health and Science University, Department of Molecular Microbiology and Immunology, MBIM 605 – Introduction to Immunology
- Oregon Health and Science University, Department of Cell, Developmental and Cancer Biology, Advanced Topics in Cancer Biology, CANB 616
- Oregon State University, Department of Biomedical Sciences, VMB 674 – Vaccines and New Therapies
| 2004 | PhD, The Scripps Research Institute ‐ Macromolecular and Cellular Structure and Chemistry | |
|
|
||
| 1997 | BS, University of California, Davis ‐ Biology | |
|
|
||